Flobow Tag Wart Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily identifiable. Plantar warts are specifically located on the soles of the feet, presenting as tender to touch and exhibiting an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a brush to ensure complete coverage of each wart. It is important to allow the application to dry fully before proceeding. This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition.

The product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes due to the potential for adverse reactions.

Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of complications.

Warnings and Precautions

For external use only; it is imperative to keep the product away from fire and flame to prevent any potential hazards.

General precautions must be observed to ensure safe application. The product should not be applied to irritated skin or any area that exhibits signs of infection or redness. Additionally, it is contraindicated for use on moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes. Patients with diabetes or those who have poor blood circulation should refrain from using this product due to increased risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought. Contact a Poison Control Center at 1-800-222-1222 without delay.

If discomfort persists after application, it is advised to discontinue use and consult a healthcare professional for further evaluation and guidance.

Side Effects

Patients should be aware that the product is for external use only and should be kept away from fire and flame to prevent any potential hazards.

In clinical practice, if discomfort persists after application, patients are advised to stop use and consult a healthcare professional. This recommendation is crucial to ensure safety and address any underlying issues that may arise from continued use.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Flobow Tag Wart Remover (salicylic acid 17% tag wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

There is currently no information available regarding the use of FLOBOW TAG WART REMOVER (salicylic acid 17% tag wart remover liquid) during pregnancy. The prescribing information does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Therefore, healthcare professionals should exercise caution when considering the use of this product in women who are pregnant or may become pregnant, as the potential risks to fetal outcomes are not established. It is advisable to weigh the benefits against any unknown risks before recommending this treatment to pregnant patients.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or a medical toxicologist may also be beneficial in managing the case effectively.

It is crucial to document all findings and interventions in the patient's medical record to ensure continuity of care and facilitate any necessary follow-up.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 if the product is swallowed.

Patients should be informed to avoid contact with their eyes. In the event that the product comes into contact with the eyes, they should flush the affected area with water for at least 15 minutes. It is important to emphasize that the product is non-edible.

Additionally, healthcare providers should instruct patients to ensure that the product is capped tightly and stored at room temperature, away from heat sources, to maintain its efficacy and safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should advise patients to avoid contact with the eyes; in the event of contact, the eye should be flushed with water for 15 minutes. The product is non-edible, and patients should discontinue use and consult a doctor if discomfort persists. In cases of ingestion, immediate medical assistance or contact with a Poison Control Center (1-800-222-1222) is advised.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Flobow Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)